The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. Read more about The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer.
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer. Read more about Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer.
Dual treatment with Val-083 and AZD1775 shows potent anti-tumor activity in diffuse midline glioma models. Read more about Dual treatment with Val-083 and AZD1775 shows potent anti-tumor activity in diffuse midline glioma models.
Integration of MRI radiomics and germline genetics to predict the IDH mutation status of gliomas. Read more about Integration of MRI radiomics and germline genetics to predict the IDH mutation status of gliomas.
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy. Read more about Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy.
Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma. Read more about Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma.
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis. Read more about Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. Read more about Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy.
Development and testing of a polygenic risk score for breast cancer aggressiveness. Read more about Development and testing of a polygenic risk score for breast cancer aggressiveness.
Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data. Read more about Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data.
